N
Nikhil I. Khushalani
Researcher at University of South Florida
Publications - 169
Citations - 8625
Nikhil I. Khushalani is an academic researcher from University of South Florida. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 26, co-authored 135 publications receiving 6087 citations. Previous affiliations of Nikhil I. Khushalani include Roswell Park Cancer Institute.
Papers
More filters
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber,Sandra P. D'Angelo,David R. Minor,F. Stephen Hodi,Ralf Gutzmer,Bart Neyns,Christoph Hoeller,Nikhil I. Khushalani,Wilson H. Miller,Christopher D. Lao,Gerald P. Linette,Luc Thomas,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Michele Maio,Mario Sznol,Paolo A. Ascierto,Peter Mohr,Bartosz Chmielowski,Alan H. Bryce,Inge Marie Svane,Jean-Jacques Grob,Angela M. Krackhardt,Christine Horak,Alexandre Lambert,Arvin Yang,James Larkin +27 more
TL;DR: Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Karl D. Lewis,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,David A. Reardon,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Ahmad A. Tarhini,Anna C. Pavlick,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +22 more
TL;DR: Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
Journal ArticleDOI
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Michael R. Migden,Danny Rischin,Chrysalyne D. Schmults,Alexander Guminski,Axel Hauschild,Karl D. Lewis,Christine H. Chung,Leonel Hernandez-Aya,Annette M. Lim,Anne Lynn S. Chang,Guilherme Rabinowits,Alesha A. Thai,Lara Dunn,Brett G.M. Hughes,Nikhil I. Khushalani,Badri Modi,Dirk Schadendorf,Bo Gao,Frank Seebach,Siyu Li,Jingjin Li,Melissa Mathias,Jocelyn Booth,Kosalai Kal Mohan,Elizabeth Stankevich,Hani M. Babiker,Irene Brana,Marta Gil-Martin,Jade Homsi,Melissa Lynne Johnson,Victor Moreno,Jiaxin Niu,Taofeek K. Owonikoko,Kyriakos P. Papadopoulos,George D. Yancopoulos,Israel Lowy,Matthew G. Fury +36 more
TL;DR: Among patients with advanced cutaneous squamous‐cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.
Journal ArticleDOI
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson,Ryan J. Sullivan,Patrick A. Ott,Matteo S. Carlino,Nikhil I. Khushalani,Fei Ye,Alexander Guminski,Igor Puzanov,Donald P. Lawrence,Elizabeth I. Buchbinder,Tejaswi V. Mudigonda,Kristen Spencer,Carolin Bender,Jenny H. Lee,Howard L. Kaufman,Alexander M. Menzies,Jessica C. Hassel,Janice M. Mehnert,Jeffrey A. Sosman,Georgina V. Long,Joseph I. Clark +20 more
TL;DR: Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipILimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion.
Journal ArticleDOI
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin,David R. Minor,Sandra P. D'Angelo,Bart Neyns,Michael Smylie,Wilson H. Miller,Ralf Gutzmer,Gerald P. Linette,Bartosz Chmielowski,Christopher D. Lao,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Mario Sznol,Adil Daud,Jeffrey A. Sosman,Nikhil I. Khushalani,Dirk Schadendorf,Christoph Hoeller,Dana Walker,George Kong,Christine Horak,Jeffrey S. Weber,Jeffrey S. Weber +23 more
TL;DR: The coprimary overall survival (OS) end point of CheckMate 037 is reported, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma.